Objective: Peripheral T-cell lymphomas (PTCLs) confer dismal prognosis and no consensus has been established on the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to its rarity and heterogeneity. The purpose was to review key points of allo-HSCT for PTCLs, including indication, times of transplantation, conditioning regimen, graft versus host disease prophylaxis, and treatment of relapse.
Data sources: A comprehensive search in PubMed and Cochrane up to February 28, 2018, with the keywords "Peripheral", "T", "Lymphoma", and "Transplantation" was done.
Study selection: Relevant articles including HSCT for PTCLs were carefully reviewed.
Results: Promising data have been reported from advances in transplant technology and more and more PTCLs patients with poor prognosis could benefit from allo-HSCT.
Conclusion: Allo-HSCT is a useful choice for patients with refractory/relapsed PTCLs or high-risk new diagnosed PTCLs.
异体造血干细胞移植治疗外周T细胞淋巴瘤的进展摘要目的：外周T细胞淋巴瘤 (PTCLs) 预后极差，且由于PTCLs发病率相对较低和异质性较强，目前尚无有关自体或异体造血干细胞移植治疗PTCLs的共识。本文旨在对异体造血干细胞治疗PTCLs的适应症、移植时机、预处理方案、移植物抗宿主病的预防和移植后复发处理等几个关键方面进行综述。 资料来源：对PubMed和Cochrane数据库中2018年2月28日以前的文章应用关键词“外周”、“T”、“淋巴瘤”和“移植”进行综合检索。 研究选择：对检索到的包含造血干细胞移植治疗外周T细胞淋巴瘤的相关文献进行详细回顾和综述。 结果：随着造血干细胞移植技术的进步，异体造血干细胞移植在PTCLs治疗中取得了令人振奋结果，越来越多预后不良的PTCLs患者可能受益于异体造血干细胞移植。 结论：异体造血干细胞移植是初治高危和复发/难治PTCLs的有效治疗措施。.
Keywords: Allogeneic; Hematopoietic Stem Cell Transplantation; Peripheral T-cell Lymphoma; Survival.